Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818767 | 1.00 | CYP11B2 (0.42) | CYP11B2IDO1ABCC9ABCB1KCNE1 | |
| SCHEMBL2818768 | 1.00 | CYP11B2 (0.42) | CYP11B2IDO1ABCC9ABCB1KCNE1 | |
| SCHEMBL2818690 | 0.79 | CYP11B2 (0.47) | CYP11B2IDO1ABCC9KCNE1KCNQ1 | |
| SCHEMBL2818687 | 0.79 | CYP11B2 (0.47) | CYP11B2IDO1ABCC9KCNE1KCNQ1 | |
| SCHEMBL2824085 | 0.78 | CYP11B2 (0.42) | CYP11B2IDO1ABCC9ABCB1KCNE1 | |
| SCHEMBL2819619 | 0.76 | CYP11B2 (0.40) | CYP11B2IDO1ABCC9KCNE1KCNQ1 | |
| SCHEMBL2819933 | 0.76 | CYP11B2 (0.40) | CYP11B2IDO1ABCC9KCNE1KCNQ1 | |
| SCHEMBL2819617 | 0.76 | CYP11B2 (0.40) | CYP11B2IDO1ABCC9KCNE1KCNQ1 | |
| SCHEMBL2818680 | 0.75 | IDO1 (0.38) | CYP11B2IDO1TDO2 | |
| SCHEMBL2821140 | 0.75 | CYP11B2 (0.60) | CYP11B2IDO1ABCC9ABCB1KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048562-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP17A1 | CYP11B2 6/4885IDO1 1361/4885ABCC9 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.